Characterization of patients with locally advanced melanoma treated at the National Institute of Oncology and Radiobiology
Keywords:
skin cancer, melanoma, locally advanced melanoma.Abstract
Introduction: Melanoma is a potentially fatal disease associated to high morbidity and mortality due to the great risk of nodal, regional and distant metastasis.
Objective: Characterize the clinical behavior of patients diagnosed with locally advanced melanoma treated at the National Institute of Oncology and Radiobiology.
Methods: A monocentric cross-sectional observational retrospective descriptive study was conducted of 79 patients with stage III locally advanced melanoma diagnosed and treated at the National Institute of Oncology and Radiobiology from January 2003 to December 2018. The median was estimated to describe the quantitative variables as measure of central tendency. Data dispersion evaluation was based on the interquartile range. A significance level of alpha = 0.05 was preset. Results are presented as tables.
Results: Mean age was 64 years. 51.9% of the patients were men and 74.7% had white skin. A personal history of pigmented lesion was reported in 53.2% of the total sample. Topographic location of the lesions in the lower limbs was described in 46.8%. 64.6% of the patients were diagnosed at stage IIIB and 35.4% at stage IIIC. Histological subtyping found that superficial spreading represented 44.1% of the sample.
Conclusions: The series of patients evaluated was characterized by a predominance of stage IIIB and the superficial spreading subtype, with main location in the lower limbs.
References
1. Infante Carbonell MC, González Calzadilla ME, Jaén Infante L, del Valle Piñera S. Melanoma cutáneo: algunas consideraciones actuales. MEDISAN. 2019; 23(1):146-164.
2. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline e Update 2016. Euro J Cancer, 2016; 63:201-217.
3. Schadendorf D, van Akkooi AC. Melanoma: diagnóstico y tratamiento. Lancet, 2018; 392:971-984.
4. Infante Carbonell MC, González Calzadilla ME, Jaén Infante L, del Valle Piñera S. Melanoma cutáneo: algunas consideraciones actuales. MEDISAN. 2019; 23(1):146-164.
5. Michielin O, Hoeller C. Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev, 2015; 41(8):660-670.
6. Gimotty PA, Elder DE, Fraker DL. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J ClinOncol, 2017; 25(9):1129-1134.
7. Nieweg OE, Gallegos-Hernández JF. La cirugía en melanoma cutáneo maligno y las nuevas drogas. Academia Mexicana de Cirugía A.C. 2015
8. Camacho Limas CP, Gerson Cwilich R, Góngora Jurado MA, Villalobos Prieto A, Blanco Vázquez YC, López Riverol O. Actualidades para el tratamiento del melanoma metastásico, estado del arte. An Med (Mex), 2017; 62(3):196-207.
9. . Mulliken J, Russak J, Rigel D. The Effect of Sunscreen in Melanoma risk. Dermatol Clin, 2014; 369-376.
10. Anuario Estadístico de Salud 2019. Dirección de Registros Médicos y Estadísticas de Salud. MINSAP, La Habana; 2020.
11. Berwick M, Erdei E, Hay J. Melanoma Epidemiology and Public Health. Dermatol Clin, 2015; 205-214.
12. Martínez-Said H, Cuéllar-Hubbe M, Barrón-Velásquez E, Padilla RA, Herrera-Gómez A, López-Graniel CM. Epidemiology of cutaneous melanoma in Mexico (1982-2002). Eur J SurgOncol. 2014; 30:163.
13. Martínez SH. El primer Consenso Nacional de Expertos en Melanoma. Gac Mex Oncol, 2015; 4(2):11-13.
14. Oficina Nacional De Estadística e Información. El Color de la Piel según el Censo de Población y Viviendas de 2012. Centro de Estudios de Población y Desarrollo. República de Cuba. La Habana, 2016.
15. Arora A, Attwood J. Common Skin Cancers and Their Precursors. Surg Clin N Am, 2014; 703-712.
16. Curin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med, 2015; 353(20):2135-2147.
17. Quiroga Mendieta L, Mendoza Lopez Videla JN, Ramos Loza CM. Melanoma maligno metatastásico: reporte de caso. Rev Med La Paz, 2017; 23(2):40-44.
18. Ramos-Álvarez M, Ruiz-Leal A, Sánchez-Dueñas L, Crocker-Sandoval A, Sánchez-Tenorio T, Orendain-Koch N, et al. Melanoma en la práctica privada en México: un diagnóstico oportuno. Dermatologia Revista Mexicana, 2015; 59(2):89-97.
19. Yabor Palomo AM, Díaz Pérez M, Peña Pérez OR, Álvarez Yabor V, Morales Fontaine A. Melanoma maligno cutáneo en pacientes de la provincia de Las Tunas. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta [revista en Internet]. 2015 [citado 11 de junio 2020]; 40 (12): [aprox. 8p]. Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/483.
20. Tuong W, Cheng L, Armstrong A. Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. Dermatol Clin, 2015; 113-124.
21. Herrera NE, Aco AY. Melanoma en México: artículo de revisión. Revista de Especialidades Médico-Quirúrgicas, 2014; 15(3):161-164.
22. García M, Díaz S, Gutiérrez A, Sánchez J, Sánchez R. Experiencia Clínica en el tratamiento adyuvante de los pacientes con melanoma de tronco y extremidades estado III en un hospital del tercer mundo 2015 19(1):125-132.
23. NIH [Internet].USA: Instituto Nacional del Cáncer de los Institutos Nacionales de la Salud de EE.UU; [Actualizado 12 de agosto de 2015; citado 11 de junio 2020]; Melanoma: Tratamiento–para profesionales de salud. Disponible en: http://www.cancer.gov/espanol/tipos/piel/pro/tratamiento-melanoma-pdq
24. Phan A, Touzets SB, Thomas BL. Acral Lentiginous Melanoma Histopathological Prognotic Features of 121 cases. BR J Clinic Dermato. 2010
25. Marchese ML, Stringa M, Valdez R. Factores pronósticos en el melanoma. Dermatol. Argent, 2017, 23(1):03-12.
